The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing ...

New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and ...

According to a recent release from GlobalData, Eli Lilly’s obesity offering could become a potential leader in the market.

A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that ...

The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.

The Food and Drug Administration (FDA) has recently approved an innovative obesity medication from Eli Lilly that hold ...

The agency's decision expands the use of Zepbound and could pave the way for Eli Lilly to gain broader insurance coverage for ...

Eli Lilly expects to launch the drug for OSA at the beginning of next year. It is the first approval beyond obesity treatment for Zepbound, which entered the market late last year and is also ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

ðÿ €üí—Õ×ï+{v7© ( dÓs]}Ý?)TLè¨0B ÓVþo­2îmŒÈ‹± úœÈûPõR==³p8{» HUõ«g{fú ñùÈ OàÈù vq 26.^f ª6[úÞfž B ÛM}ÿ!¤1‹ Ù ôêP>PuÁé)â&ø¿ÑÝ ¦[n ü¸Ø ...

The FDA has cleared Eli Lilly’s obesity drug Zepbound as the first treatment for obstructive sleep apnea in the U.S.